ライフサイエンスコーパス: oxidosqualene

1 -amyrin, a product of the cyclization of 2,3-oxidosqualene.

2 he suicide substrate (3S)-29-methylidene-2,3-oxidosqualene.

3 reospecific conversion of squalene to 2,3(S)-oxidosqualene, a key step in cholesterol biosynthesis.

4 ith no stable intermediates between 2,3-( S)-oxidosqualene and friedelin.

5 LAS) and cycloartenol synthase (CAS) use 2,3-oxidosqualene as their substrate to produce lanosterol a

6 2,3-( S)-Oxidosqualene (C 30H 50O) serves as a versatile starting

7 nthesis of cholesterol) from the acyclic 2,3-oxidosqualene catalyzed by oxidosqualene cyclase (OSC) h

8 rential cyclization and rearrangement of 2,3-oxidosqualene controlled by oxidosqualene cyclases (OSCs

9 cerevisiae led to the identification of one oxidosqualene cyclase (MlbAS) and two cytochrome P450s,

10 we identify and functionally characterize an oxidosqualene cyclase (OeBAS) required for the productio

11 on of 2,3-oxidosqualene to lanosterol by the oxidosqualene cyclase (OSC) enzyme lanosterol synthase (

12 m the acyclic 2,3-oxidosqualene catalyzed by oxidosqualene cyclase (OSC) has stimulated the interest

13 Small-molecule oxidosqualene cyclase (OSC) inhibitors were found to be

14 We identify an oxidosqualene cyclase able to produce the potential 30-c

15 e containing the ets2-1 allele show weakened oxidosqualene cyclase activity.

16 coenzyme A reductase but also inhibitors of oxidosqualene cyclase decrease tumor growth, suggesting

17 t the E. adriatica eudoraenol synthase is an oxidosqualene cyclase homologous to bacterial lanosterol

18 lioblastoma cells were also demonstrated for oxidosqualene cyclase inhibitors in combination with ato

19 Ten oxidosqualene cyclase inhibitors with high efficacy as c

20 From 1,891 oxidosqualene cyclase sequences representing the diversi

21 and 12 protein gene sequences for eukaryotic oxidosqualene cyclase were compared with all available c

22 Two enzymes, squalene monooxygenase and oxidosqualene cyclase, are the minimum necessary for ini

23 ough transcriptome analysis of the roots, an oxidosqualene cyclase, OsONS1, was identified that produ

24 y program in which we combined CYP716Y1 with oxidosqualene cyclase, P450, and glycosyltransferase gen

25 Compounds were optimized against oxidosqualene cyclase-lanosterol synthase (OSC) inhibiti

26 Two MeJA-responsive oxidosqualene cyclases (ObAS1 and ObAS2) that encode for

27 Oxidosqualene cyclases (OSCs) catalyze the first committ

28 Many functionally promiscuous plant 2,3-oxidosqualene cyclases (OSCs) have been found, but compl

29 ly shaped by the first-committed enzyme, 2,3-oxidosqualene cyclases (OSCs) in plant triterpene biosyn

30 Oxidosqualene cyclases (OSCs) positioned at a key metabo

31 rangement of 2,3-oxidosqualene controlled by oxidosqualene cyclases (OSCs) represents one of the most

32 Triterpene skeletons, catalyzing by 2,3-oxidosqualene cyclases (OSCs), are essential for synthes

33 other plants, triterpenoids are generated by oxidosqualene cyclases (OSCs).

34 terpene skeletons catalyzed by different 2,3-oxidosqualene cyclases (OSCs).

35 y of triterpenoids in plants is generated by oxidosqualene cyclases based on epoxide-triggered cation

36 milarity networks to search for noncanonical oxidosqualene cyclases that might produce triterpene ste

37 model plant Arabidopsis thaliana encodes 13 oxidosqualene cyclases, 9 of which have been characteriz

38 uilding on proven methods for characterizing oxidosqualene cyclases, we heterologously expressed in y

39 keletons of these compounds are generated by oxidosqualene cyclases, which carry out a polycyclizatio

40 the stereochemical space accessible by known oxidosqualene cyclases.

41 e indispensable enzymatic cyclization of 2,3-oxidosqualene for varied triterpenoid biosynthesis.

42 e catalyses the oxidation of squalene to 2,3-oxidosqualene in the cholesterol synthesis pathway and i

43 zation of the linear 30 carbon precursor 2,3-oxidosqualene into different triterpene scaffolds.

44 Genetic manipulation of oxidosqualene-lanosterol cyclase did result in the build

45 genetic and pharmacological manipulation of oxidosqualene-lanosterol cyclase, that an oxysterol-deri

46 The effects of inhibitors of 2,3-oxidosqualene:lanosterol cyclase (cyclase) on cytochrome

47 A new orally active oxidosqualene:lanosterol cyclase (OSLC) inhibitor showed

48 ith a 1000-fold molar excess of 18-thia-2, 3-oxidosqualene or the nonterpenoid inhibitor BIBX79.

49 Five sulfur-containing analogues of 2,3-oxidosqualene (OS) were evaluated as inhibitors of squal

50 chair-chair-boat conformation of the (S)-2,3-oxidosqualene precursor during the cyclization process,

51 utions also suggested cyclization of the 2,3-oxidosqualene precursor into the solanidine aglycone bac

52 pathway elucidation, we demonstrate that the oxidosqualene synthase catalysing the first committed st

53 Squalene epoxidase converts squalene into oxidosqualene, the precursor of all known angiosperm cyc

54 st common intermediate in the cyclization of oxidosqualene to a diverse array of secondary triterpene

55 is a beta-amyrin synthase that converts 2,3-oxidosqualene to beta-amyrin in yeast, and its role in m

56 the isoprenoid pathway by cyclization of 2,3-oxidosqualene to cycloartenol.

57 hesis in animals involves cyclization of 2,3-oxidosqualene to lanosterol by the oxidosqualene cyclase

58 teroid hormones is the conversion of (S)-2,3-oxidosqualene to lanosterol.

59 Plants also convert 2,3-oxidosqualene to other sterol-like cyclization products,

60 bstrate dioxidosqualene in preference to 2,3-oxidosqualene when expressed in yeast.

61 s synthesized through the cyclization of 2,3-oxidosqualene, with the highest number of rearrangements